Eli Lilly and Company (LLY) Announces New Phase 3 Trial Results for Orforglipron

Eli Lilly and Company (NYSE:LLY) is one of the Stocks With Huge Catalysts on the Horizon. On July 21, Eli Lilly and Company (NYSE:LLY) announced new Phase 3 trial results for Orforglipron, which is an oral drug for adults with type 2 diabetes.

This comes as a breakthrough for the company as Orforglipron is the first non-injectable GLP-1 receptor agonist to show strong results in this type of trial. The results showed that at 40 weeks, all tested doses of Orforglipron significantly lowered A1C. Moreover, the two highest doses also led to meaningful and statistically significant weight loss.

The safety profile of the drug was also consistent, as the most common side effects were mild-to-moderate stomach issues like diarrhea and nausea, mostly during dose increases. In addition, discontinuation due to side effects was similar to other drugs in this class. The company expects to share topline results from ACHIEVE-2 later this year. In this trial, Orforglipron will be compared with dapagliflozin. The company remains on track to submit Orforglipron for weight management to global regulatory agencies by the end of this year and for type 2 diabetes by 2026.

Eli Lilly and Company (NYSE:LLY) is an international pharmaceutical company that focuses on treatments for diabetes, oncology, immunology, neuroscience, and cardiometabolic health.

Advanced Micro Devices, Inc. (NASDAQ:LLY) is an international semiconductor company that designs and sells high-performance processors and graphics chips used in data centers.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.